
A recent hepatocellular carcinoma (HCC) therapy study unveiled a pivotal role for RNA binding motif protein 45 (RBM45) in tumor progression. Elevated in HCC patients, RBM45 drives cell proliferation and tumor growth. Notably, RBM45 enhances the stability of the glutamine transporter ASCT2 by thwarting lysosomal degradation, fueling HCC development. Targeting this RBM45-ASCT2 interaction with AG-221, originally a mIDH2 inhibitor for leukemia, curbed ASCT2 stability and slowed HCC progression. This discovery offers new avenues for designing ASCT2 inhibitors and potential HCC drug development strategies.
Like
Save
Share